share_log

T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers

T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers

T2 Biosystems | S-3：特定交易注册声明
美股SEC公告 ·  05/28 18:06

Moomoo AI 已提取核心信息

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on May 24, 2024. The registration pertains to the resale of up to 6,217,723 shares of common stock by selling stockholders. These shares include 1,700,000 currently outstanding shares, shares issuable upon the exercise of various warrants acquired in a private placement transaction on May 17, 2024, and shares issuable upon the exercise of Wainwright Warrants. T2 Biosystems will not sell any shares or receive proceeds from the selling stockholders' sales, but will receive proceeds if the warrants are exercised for cash. The selling stockholders will cover all commissions and discounts from their sales, while T2 Biosystems will bear all other costs associated with the registration. The common stock is traded on The NASDAQ Capital Market under the symbol 'TTOO', with the last reported sale price being $5.16 per share as of May 23, 2024. The company cautions that investing in its common stock involves a high degree of risk.
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on May 24, 2024. The registration pertains to the resale of up to 6,217,723 shares of common stock by selling stockholders. These shares include 1,700,000 currently outstanding shares, shares issuable upon the exercise of various warrants acquired in a private placement transaction on May 17, 2024, and shares issuable upon the exercise of Wainwright Warrants. T2 Biosystems will not sell any shares or receive proceeds from the selling stockholders' sales, but will receive proceeds if the warrants are exercised for cash. The selling stockholders will cover all commissions and discounts from their sales, while T2 Biosystems will bear all other costs associated with the registration. The common stock is traded on The NASDAQ Capital Market under the symbol 'TTOO', with the last reported sale price being $5.16 per share as of May 23, 2024. The company cautions that investing in its common stock involves a high degree of risk.
T2 Biosystems, Inc. 是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者，已于2024年5月24日向美国证券交易委员会（SEC）提交了S-3表格注册声明。该注册涉及通过出售股东转售多达6,217,723股普通股。这些股票包括目前已发行的1,700,000股股票、在行使2024年5月17日私募交易中收购的各种认股权证后可发行的股票以及在行使温赖特认股权证时可发行的股份。T2 Biosystems不会出售任何股票或从出售股东的销售中获得收益，但如果认股权证以现金行使，则将获得收益。出售股东将支付其销售中的所有佣金和折扣，而T2 Biosystems将承担与注册相关的所有其他费用。普通股在纳斯达克资本市场上交易，股票代码为 “TTOO”，截至2024年5月23日，最新公布的销售价格为每股5.16美元。该公司警告说，投资普通股涉及高度的风险。
T2 Biosystems, Inc. 是快速检测诱发败血症的病原体和抗生素耐药基因领域的领导者，已于2024年5月24日向美国证券交易委员会（SEC）提交了S-3表格注册声明。该注册涉及通过出售股东转售多达6,217,723股普通股。这些股票包括目前已发行的1,700,000股股票、在行使2024年5月17日私募交易中收购的各种认股权证后可发行的股票以及在行使温赖特认股权证时可发行的股份。T2 Biosystems不会出售任何股票或从出售股东的销售中获得收益，但如果认股权证以现金行使，则将获得收益。出售股东将支付其销售中的所有佣金和折扣，而T2 Biosystems将承担与注册相关的所有其他费用。普通股在纳斯达克资本市场上交易，股票代码为 “TTOO”，截至2024年5月23日，最新公布的销售价格为每股5.16美元。该公司警告说，投资普通股涉及高度的风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间